Mallinckrodt plc announced it has appointed Lisa French as Executive Vice President and Chief Commercial Officer, effective October 1, 2022. Ms. French brings more than 30 years of commercial biopharmaceutical experience and will oversee the development and execution of Mallinckrodt's commercialization strategy. Ms. French will serve on the Executive Committee and succeeds Hugh O'Neill, who departed Mallinckrodt as of September 16, 2022.
Ms. French most recently built and led the U.S. Women's Health Commercial team for Organon & Co. following its spin-off from Merck. Previously, she held numerous leadership positions at Merck, where she ultimately led all aspects of a multibillion-dollar brand, executed commercial innovation initiatives and oversaw multiple sales teams.
Siggi Olafsson, President and Chief Executive Officer, said, "I am delighted to welcome Lisa to Mallinckrodt as our new Chief Commercial Officer and a member of our Executive Committee. Lisa brings decades of commercialization experience, with deep expertise and a proven track record developing and implementing effective and growth-oriented commercialization strategies. I am confident her insights and experience will be invaluable as we continue working to advance our branded pipeline, bring Mallinckrodt's existing products to new markets and geographies and stabilize our portfolio – all for the benefit of our patients, shareholders and other stakeholders."
Ms. French said, "One of the reasons I was drawn to Mallinckrodt is the Company's focus on innovative, drug development and commercialization for underserved patients with severe and critical conditions. The Company's portfolio benefits from core products with established track records and strong brand recognition. I look forward to working closely with Siggi and the Mallinckrodt team to build on this strong foundation."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!